Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Cash (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Change in Cash for 15 consecutive years, with -$2.6 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 998.28% to -$2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Dec 2025, up 1007.83% year-over-year, with the annual reading at $10.9 million for FY2025, 467.44% up from the prior year.
  • Change in Cash for Q4 2025 was -$2.6 million at Aytu Biopharma, down from $1.7 million in the prior quarter.
  • The five-year high for Change in Cash was $12.8 million in Q2 2025, with the low at -$9.3 million in Q3 2021.
  • Average Change in Cash over 5 years is -$882368.4, with a median of -$322000.0 recorded in 2023.
  • Peak annual rise in Change in Cash hit 5094.72% in 2025, while the deepest fall reached 1063.2% in 2025.
  • Over 5 years, Change in Cash stood at -$5.3 million in 2021, then rose by 18.42% to -$4.3 million in 2022, then skyrocketed by 89.91% to -$435000.0 in 2023, then soared by 166.67% to $290000.0 in 2024, then crashed by 998.28% to -$2.6 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$2.6 million, $1.7 million, and $12.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.